1. Home
  2. CWCO vs DSGN Comparison

CWCO vs DSGN Comparison

Compare CWCO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CWCO
  • DSGN
  • Stock Information
  • Founded
  • CWCO 1973
  • DSGN 2017
  • Country
  • CWCO Cayman Islands
  • DSGN United States
  • Employees
  • CWCO N/A
  • DSGN N/A
  • Industry
  • CWCO Water Supply
  • DSGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CWCO Utilities
  • DSGN Health Care
  • Exchange
  • CWCO Nasdaq
  • DSGN Nasdaq
  • Market Cap
  • CWCO 402.4M
  • DSGN 348.2M
  • IPO Year
  • CWCO N/A
  • DSGN 2021
  • Fundamental
  • Price
  • CWCO $27.53
  • DSGN $4.91
  • Analyst Decision
  • CWCO
  • DSGN Hold
  • Analyst Count
  • CWCO 0
  • DSGN 3
  • Target Price
  • CWCO N/A
  • DSGN $7.00
  • AVG Volume (30 Days)
  • CWCO 71.3K
  • DSGN 126.2K
  • Earning Date
  • CWCO 03-26-2025
  • DSGN 03-18-2025
  • Dividend Yield
  • CWCO 1.60%
  • DSGN N/A
  • EPS Growth
  • CWCO 71.40
  • DSGN N/A
  • EPS
  • CWCO 2.31
  • DSGN N/A
  • Revenue
  • CWCO $158,810,010.00
  • DSGN N/A
  • Revenue This Year
  • CWCO N/A
  • DSGN N/A
  • Revenue Next Year
  • CWCO $8.67
  • DSGN N/A
  • P/E Ratio
  • CWCO $16.57
  • DSGN N/A
  • Revenue Growth
  • CWCO 2.20
  • DSGN N/A
  • 52 Week Low
  • CWCO $23.55
  • DSGN $2.45
  • 52 Week High
  • CWCO $33.34
  • DSGN $7.77
  • Technical
  • Relative Strength Index (RSI)
  • CWCO 59.85
  • DSGN 53.37
  • Support Level
  • CWCO $27.00
  • DSGN $3.58
  • Resistance Level
  • CWCO $28.42
  • DSGN $5.17
  • Average True Range (ATR)
  • CWCO 0.66
  • DSGN 0.40
  • MACD
  • CWCO 0.08
  • DSGN 0.11
  • Stochastic Oscillator
  • CWCO 67.40
  • DSGN 83.65

About CWCO Consolidated Water Co. Ltd.

Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties, and The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal and industrial water production, supply and treatment.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: